ilShinbiobase Co. Ltd (068330) — Cash Flow Reinvestment Rate
ilShinbiobase Co. Ltd (068330) has a Cash Flow Reinvestment Rate of 1.39x as of March 2026, reinvesting ₩4.79 Billion (capex ₩38.55 Million plus investments ₩-4.75 Billion) from operating cash flow of ₩3.46 Billion. Check ilShinbiobase Co. Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
ilShinbiobase Co. Ltd Cash Flow Reinvestment Rate (2014–2025)
Historical reinvestment intensity for ilShinbiobase Co. Ltd across 12 annual periods. Explore 068330 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for ilShinbiobase Co. Ltd (2014–2025)
Year-by-year capital reinvestment analysis for ilShinbiobase Co. Ltd. For live market cap and broader valuation context, see ilShinbiobase Co. Ltd (068330) total market value.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.90x | ₩4.73 Billion | ₩5.27 Billion | ₩20.64 Million | ▼ -20.7% |
| 2024 | 1.13x | ₩4.66 Billion | ₩4.12 Billion | ₩53.53 Million | ▲ +15.3% |
| 2023 | 0.98x | ₩5.81 Billion | ₩5.92 Billion | ₩262.17 Million | ▼ -68.2% |
| 2022 | 3.09x | ₩8.18 Billion | ₩2.65 Billion | ₩522.59 Million | ▲ +14888.1% |
| 2021 | 0.02x | ₩139.12 Million | ₩6.74 Billion | ₩139.12 Million | ▼ -89.6% |
| 2020 | 0.20x | ₩892.64 Million | ₩4.50 Billion | ₩892.64 Million | ▼ -76.9% |
| 2019 | 0.86x | ₩4.77 Billion | ₩5.55 Billion | ₩245.41 Million | ▲ +140.1% |
| 2018 | 0.36x | ₩1.75 Billion | ₩4.88 Billion | ₩385.81 Million | ▲ +0.9% |
| 2017 | 0.35x | ₩749.79 Million | ₩2.11 Billion | ₩407.59 Million | ▼ -83.8% |
| 2016 | 2.19x | ₩6.59 Billion | ₩3.01 Billion | ₩271.94 Million | ▲ +101.5% |
| 2015 | 1.09x | ₩293.89 Million | ₩270.22 Million | ₩99.39 Million | ▲ +2627.6% |
| 2014 | 0.04x | ₩132.61 Million | ₩3.33 Billion | ₩101.50 Million | — |